IM Cannabis Corp. (NASDAQ:IMCC) Short Interest Down 38.0% in February

IM Cannabis Corp. (NASDAQ:IMCC) was the recipient of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 19,228 shares, a decrease of 38.0% from the January 29th total of 30,993 shares. Based on an average trading volume of 38,381 shares, the short-interest ratio is currently 0.5 days. Approximately 0.3% of the company’s stock are sold short. Approximately 0.3% of the company’s stock are sold short. Based on an average trading volume of 38,381 shares, the short-interest ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IM Cannabis in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

IM Cannabis Stock Performance

IMCC stock opened at $0.68 on Friday. The stock’s 50 day simple moving average is $1.26 and its 200 day simple moving average is $1.63. The company has a current ratio of 0.82, a quick ratio of 0.56 and a debt-to-equity ratio of 0.25. IM Cannabis has a 12-month low of $0.68 and a 12-month high of $7.12. The stock has a market capitalization of $4.01 million, a PE ratio of -0.87 and a beta of 2.10.

Institutional Investors Weigh In On IM Cannabis

Several large investors have recently bought and sold shares of the business. Hidden Cove Wealth Management LLC bought a new position in IM Cannabis during the 3rd quarter valued at about $27,000. DRW Securities LLC purchased a new position in shares of IM Cannabis during the fourth quarter valued at approximately $32,000. Heron Bay Capital Management bought a new position in IM Cannabis during the second quarter valued at approximately $195,000. Finally, Yorkville Advisors Global LP purchased a new stake in IM Cannabis in the third quarter worth approximately $1,452,000. 7.68% of the stock is currently owned by institutional investors.

IM Cannabis Company Profile

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.